Gay A - Search Results

1

Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE).

Green JB, Mottl AK, Bakris G, Heerspink HJL, Mann JFE, McGill JB, Nangaku M, Rossing P, Scott C, Gay A, Agarwal R. Green JB, et al. Among authors: gay a. Nephrol Dial Transplant. 2023 Mar 31;38(4):894-903. doi: 10.1093/ndt/gfac198. Nephrol Dial Transplant. 2023. PMID: 35700142 Free PMC article. Clinical Trial.

2

Patient characteristics and initiation of mineralocorticoid receptor antagonists in patients with chronic kidney disease in routine clinical practice in the US: a retrospective cohort study.

Blankenburg M, Fett AK, Eisenring S, Haas G, Gay A. Blankenburg M, et al. Among authors: gay a. BMC Nephrol. 2019 May 16;20(1):171. doi: 10.1186/s12882-019-1348-4. BMC Nephrol. 2019. PMID: 31096928 Free PMC article.

3

Disease characteristics and outcomes in patients with chronic kidney disease and type 2 diabetes: a matched cohort study of spironolactone users and non-users.

Blankenburg M, Kovesdy CP, Fett AK, Griner RG, Gay A. Blankenburg M, et al. Among authors: gay a. BMC Nephrol. 2020 Feb 26;21(1):61. doi: 10.1186/s12882-020-01719-7. BMC Nephrol. 2020. PMID: 32101152 Free PMC article.

4

Cardiovascular and Renal Outcomes in Patients with Type-2 Diabetes and Chronic Kidney Disease Identified in a United States Administrative Claims Database: A Population Cohort Study.

Folkerts K, Kelly AMB, Petruski-Ivleva N, Fried L, Blankenburg M, Gay A, Velentgas P, Kovesdy CP. Folkerts K, et al. Among authors: gay a. Nephron. 2021;145(4):342-352. doi: 10.1159/000513782. Epub 2021 Mar 31. Nephron. 2021. PMID: 33789294

5

Chronic kidney disease progression among patients with type 2 diabetes identified in US administrative claims: a population cohort study.

Kovesdy CP, Isaman D, Petruski-Ivleva N, Fried L, Blankenburg M, Gay A, Velentgas P, Folkerts K. Kovesdy CP, et al. Among authors: gay a. Clin Kidney J. 2020 Dec 28;14(6):1657-1664. doi: 10.1093/ckj/sfaa200. eCollection 2021 Jun. Clin Kidney J. 2020. PMID: 34084461 Free PMC article.

6

Design and rationale of FINE-REAL: A prospective study of finerenone in clinical practice.

Desai NR, Navaneethan SD, Nicholas SB, Pantalone KM, Wanner C, Hamacher S, Gay A, Wheeler DC. Desai NR, et al. Among authors: gay a. J Diabetes Complications. 2023 Apr;37(4):108411. doi: 10.1016/j.jdiacomp.2023.108411. Epub 2023 Feb 2. J Diabetes Complications. 2023. PMID: 36857997 Free article.

7

Adherence to Chronic Kidney Disease Screening Guidelines Among Patients With Type 2 Diabetes in a US Administrative Claims Database.

Folkerts K, Petruski-Ivleva N, Comerford E, Blankenburg M, Evers T, Gay A, Fried L, Kovesdy CP. Folkerts K, et al. Among authors: gay a. Mayo Clin Proc. 2021 Apr;96(4):975-986. doi: 10.1016/j.mayocp.2020.07.037. Epub 2021 Mar 12. Mayo Clin Proc. 2021. PMID: 33722396 Free article.

8

Predictive Risk Models to Identify Patients at High-Risk for Severe Clinical Outcomes With Chronic Kidney Disease and Type 2 Diabetes.

Sheer R, Nair R, Pasquale MK, Evers T, Cockrell M, Gay A, Singh R, Schmedt N. Sheer R, et al. Among authors: gay a. J Prim Care Community Health. 2022 Jan-Dec;13:21501319211063726. doi: 10.1177/21501319211063726. J Prim Care Community Health. 2022. PMID: 35068244 Free PMC article.

9

Annual health care resource utilization and cost among type 2 diabetes patients with newly recognized chronic kidney disease within a large U.S. administrative claims database.

Folkerts K, Petruski-Ivleva N, Kelly A, Fried L, Blankenburg M, Gay A, Kovesdy CP. Folkerts K, et al. Among authors: gay a. J Manag Care Spec Pharm. 2020 Dec;26(12):1506-1516. doi: 10.18553/jmcp.2020.26.12.1506. J Manag Care Spec Pharm. 2020. PMID: 33251992 Free PMC article.

Patients identified at stage 5 CKD incurred on average $110,210 of total annual cost and had roughly a 7-fold higher annual inpatient hospitalization rate compared with patients identified at stage 1 CKD. ...Fried received consultant fees from Bayer, Novo Nordisk, and Bris …

Patients identified at stage 5 CKD incurred on average $110,210 of total annual cost and had roughly a 7-fold higher annual inpatient …

10

The Net Clinical Outcome of Dual-Pathway Inhibition in Clinical Practice: The "Xarelto plus Acetylsalicylic Acid: Treatment Patterns and Outcomes in Patients with Atherosclerosis" Registry.

Breitenstein A, Gay A, Vogtländer K, Fox KAA, Steffel J; XATOA Publication Committee. Breitenstein A, et al. Among authors: gay a. J Clin Med. 2024 Mar 28;13(7):1956. doi: 10.3390/jcm13071956. J Clin Med. 2024. PMID: 38610724 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

513 results

Search Page